Literature DB >> 19780153

Tyrosine polyethylene glycol (PEG)-micelle magnetic resonance contrast agent for the detection of lipid rich areas in atherosclerotic plaque.

Anne Beilvert1, David P Cormode, Frédéric Chaubet, Karen C Briley-Saebo, Venkatesh Mani, Willem J M Mulder, Esad Vucic, Jean-François Toussaint, Didier Letourneur, Zahi A Fayad.   

Abstract

Vulnerable or high-risk atherosclerotic plaques often exhibit large lipid cores and thin fibrous caps that can lead to deadly vascular events when they rupture. In this study, polyethylene glycol (PEG)-micelles that incorporate a gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA) amphiphile were used as an MR contrast agent. In an approach inspired by lipoproteins, the micelles were functionalized with tyrosine residues, an aromatic, lipophilic amino acid, to reach the lipid-rich areas of atherosclerotic plaque in a highly efficient manner. These micelles were applied to apolipoprotein E(-/-) (ApoE(-/-)) mice as a model of atherosclerosis. The abdominal aortas of the animals were imaged using T(1)-weighted (T(1)W) high-resolution MRI at 9.4T before and up to 48 h after the administration of the micelles. PEG-micelles modified with 15% tyrosine residues yielded a significant enhancement of the abdominal aortic wall at 6 and 24 h postinjection (pi) as compared to unmodified micelles. Fluorescence microscopy on histological sections of the abdominal aorta showed a correlation between lipid-rich areas and the distribution of the functionalized contrast agent in plaque. Using a simple approach, we demonstrated that lipid-rich areas in atherosclerotic plaque of ApoE(-/-) mice can be detected by MRI using Gd-DTPA micelles.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19780153      PMCID: PMC2829093          DOI: 10.1002/mrm.22103

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  43 in total

Review 1.  Is there a vulnerable plaque?

Authors:  Attilio Maseri; Valentin Fuster
Journal:  Circulation       Date:  2003-04-29       Impact factor: 29.690

Review 2.  A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association.

Authors:  H C Stary; A B Chandler; R E Dinsmore; V Fuster; S Glagov; W Insull; M E Rosenfeld; C J Schwartz; W D Wagner; R W Wissler
Journal:  Circulation       Date:  1995-09-01       Impact factor: 29.690

Review 3.  Mouse models of experimental atherosclerosis.

Authors:  J Jawień; P Nastałek; R Korbut
Journal:  J Physiol Pharmacol       Date:  2004-09       Impact factor: 3.011

4.  Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine.

Authors:  G M Anantharamaiah; J L Jones; C G Brouillette; C F Schmidt; B H Chung; T A Hughes; A S Bhown; J P Segrest
Journal:  J Biol Chem       Date:  1985-08-25       Impact factor: 5.157

5.  Aromatic residue position on the nonpolar face of class a amphipathic helical peptides determines biological activity.

Authors:  Geeta Datta; Raquel F Epand; Richard M Epand; Manjula Chaddha; Matthew A Kirksey; David W Garber; Sissel Lund-Katz; Michael C Phillips; Susan Hama; Mohamad Navab; Alan M Fogelman; Mayakonda N Palgunachari; Jere P Segrest; G M Anantharamaiah
Journal:  J Biol Chem       Date:  2004-04-08       Impact factor: 5.157

Review 6.  Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs.

Authors:  Anatoly N Lukyanov; Vladimir P Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2004-05-07       Impact factor: 15.470

7.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.

Authors:  Y Nakashima; A S Plump; E W Raines; J L Breslow; R Ross
Journal:  Arterioscler Thromb       Date:  1994-01

8.  Micelles from polyethylene glycol/phosphatidylethanolamine conjugates for tumor drug delivery.

Authors:  Anatoly N Lukyanov; Zhonggao Gao; Vladimir P Torchilin
Journal:  J Control Release       Date:  2003-08-28       Impact factor: 9.776

9.  Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging.

Authors:  Marc Sirol; Vitalii V Itskovich; Venkatesh Mani; Juan Gilberto S Aguinaldo; John T Fallon; Bernd Misselwitz; Hanns-Joachim Weinmann; Valentin Fuster; Jean-François Toussaint; Zahi A Fayad
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

10.  Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo.

Authors:  J F Toussaint; G M LaMuraglia; J F Southern; V Fuster; H L Kantor
Journal:  Circulation       Date:  1996-09-01       Impact factor: 29.690

View more
  10 in total

1.  The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice.

Authors:  Thaddeus J Wadas; Christopher D Sherman; Jeffrey H Miner; James R Duncan; Carolyn J Anderson
Journal:  Magn Reson Med       Date:  2010-11       Impact factor: 4.668

2.  Flat-panel versus 64-channel computed tomography for in vivo quantitative characterization of aortic atherosclerotic plaques.

Authors:  Ibrahim Aboshady; Dianna D Cody; Evan M Johnson; Amir Gahremanpour; Deborah Vela; Kamal G Khalil; Herbert L Dupont; James T Willerson; L Maximilian Buja; Gregory W Gladish
Journal:  Int J Cardiol       Date:  2010-12-24       Impact factor: 4.164

Review 3.  Imaging biomarkers of cardiovascular disease.

Authors:  Jinnan Wang; Niranjan Balu; Gador Canton; Chun Yuan
Journal:  J Magn Reson Imaging       Date:  2010-09       Impact factor: 4.813

Review 4.  Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis.

Authors:  Daniel R Lewis; Kubra Kamisoglu; Adam W York; Prabhas V Moghe
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-04-26

5.  One-Pot, One-Step Synthesis of Drug-Loaded Magnetic Multimicelle Aggregates.

Authors:  Chang Soo Kim; Dmitry Nevozhay; Rebeca Romero Aburto; Ashok Pehere; Lan Pang; Rebecca Dillard; Ziqiu Wang; Clayton Smith; Kelsey Boitnott Mathieu; Marie Zhang; John D Hazle; Robert C Bast; Konstantin Sokolov
Journal:  Bioconjug Chem       Date:  2022-05-06       Impact factor: 6.069

6.  Gadolinium-Based Contrast Agents for Vessel Wall Magnetic Resonance Imaging (MRI) of Atherosclerosis.

Authors:  Claudia Calcagno; Sarayu Ramachandran; Antoine Millon; Philip M Robson; Venkatesh Mani; Zahi Fayad
Journal:  Curr Cardiovasc Imaging Rep       Date:  2012-10-14

7.  Molecular imaging with optical coherence tomography using ligand-conjugated microparticles that detect activated endothelial cells: rational design through target quantification.

Authors:  Andrew Jefferson; Rohan S Wijesurendra; Martina A McAteer; Janet E Digby; Gillian Douglas; Thomas Bannister; Francisco Perez-Balderas; Zsolt Bagi; Alistair C Lindsay; Robin P Choudhury
Journal:  Atherosclerosis       Date:  2011-08-05       Impact factor: 5.162

8.  Gadolinium-Functionalized Peptide Amphiphile Micelles for Multimodal Imaging of Atherosclerotic Lesions.

Authors:  Sang Pil Yoo; Federico Pineda; John C Barrett; Christopher Poon; Matthew Tirrell; Eun Ji Chung
Journal:  ACS Omega       Date:  2016-11-21

Review 9.  Cardiovascular magnetic resonance in carotid atherosclerotic disease.

Authors:  Li Dong; William S Kerwin; Marina S Ferguson; Rui Li; Jinnan Wang; Huijun Chen; Gador Canton; Thomas S Hatsukami; Chun Yuan
Journal:  J Cardiovasc Magn Reson       Date:  2009-12-15       Impact factor: 5.364

10.  PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder.

Authors:  Anna Brown; Siddharth Patel; Carl Ward; Anna Lorenz; Mauren Ortiz; Allison DuRoss; Fabian Wieghardt; Amanda Esch; Elsje G Otten; Laura M Heiser; Viktor I Korolchuk; Conroy Sun; Sovan Sarkar; Gaurav Sahay
Journal:  Sci Rep       Date:  2016-08-30       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.